Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4771-4780

  Varveris, Haralambos ^a   Delakas, D ^a   Anezinis, P ^a   Haldeopoulos, Demitrios ^a   Mazonakis, Michael ^a   Damilakis, J ^a   Metaxaris, George ^a   Chondros, Nikolaos ^a   Mavromanolakis, Emmanuel ^a   Daskalopoulos, G ^c   Dimitrakopoulos, Aristidis ^b   Kranidis, Angelos ^a  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^b Venizelion General Hospital   (Greece)

^c NONE

Author keywords

Bladder cancer; Cisplatinum; Docetaxel radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLADDER CARCINOMA; BONE MARROW TOXICITY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MOTOR DYSFUNCTION; MYALGIA; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URETER OBSTRUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY; RECURRENCE; SURVIVAL RATE; TAXOIDS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0031418094     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Parsons JT, Million RR: Bladder. In: Principles and Practice of Radiation oncology by CA Perez, LW Brady 2nd Edn. JB Lippincott company 1992.
2. Fair WR, Fuks ZY, Scher HI: Cancer of the Bladder. In: Cancer Principles Practice of Oncology 4th Edn VT DeVita, S Hellman, S Rosenberg, JB Lippincott company 1994.
3. Miller LS: Bladder cancer: superiority of preoperative irradiation therapy and cystectomy in clinical stages B2 and C Cancer, Suppl. 2, 39: 973, 1977.
4. Goodman G, Hislop T, Elwood J, Balfour J: Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy. Int J Rad Onc Biol Phys 7: 569, 1981.
5. Gofflnet D, Schneider M, Glastein E, Ludwig H, Ray G, Dunnick N, Bagshaw M: Bladder cancer: results of radiation therapy in 384 patients. Radiology 117: 149, 1975.
6. Bloom H, Hendry W, Wallace D, Skeet R: Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Brit J Urol 54: 136, 1992.
7. Logothetis C, Samuels M, Ogden S, Dexeus F, Johnson D, Svanson D, von Eschenbach A: Adjuvant chemotherapy for invasive bladder carcinoma: a preliminary report. Proc Am Soc Clin Oncol 4: 108, 1986.
8. Soloway MS: Is there a role for induction therapy for locally advanced bladder cancer ? Urology 29: 577-583, 1987.
9. Havesteen H, von der Maase H, Stroyer J, Rasmussen F: Cisplatin as a firat line treatment in T2 and T3 bladder carcinoma Cancer Treat Rep 71: 1285-1287, 1987.
10. Daniels JR, Skinner DG, Lieskovsky G, Turcillo P, Daniels AM, Krailo M: Adjuvant chemotherapy following radical cystectomy for carcinoma of the bladder: a randomized trial. Proc Am Soc Clin Oncol 4: 105, 1986.
11. Batata M, Chu F, Hilaris B, Kim Y, Lee M, Chung S, Whitmore W: Factors of prognostic and therapeutic significance in patients with bladder cancer. Int J Rad One Biol Phy 7: 575-579, 1981.
12. Quilty P, Duncan W: Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control Int J Rad Onc Biol Phys 12: 853-860, 1986.
13. Yu W, Sagerman R, Chung C, Dalal P, King G: Bladder carcinoma. Experience with radical and preoperative radiotherapy in 421 patients. Cancer 56: 1293-1299, 1985.
14. Shipley W, Rose M, Perrore T, Mannix C, Heney N, Prout G: Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol 134: 679-683, 1985.
15. Shipley W, Prout G, Kaufman S, Perrore T: Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full dose irradiation. Cancer 60: 514-520, 1987b.
16. Richie I, Shipley W, Yagoda A: Cancer of the bladder. In: Principles and practice of oncology 2nd Edn De Vita V, Hellman S, Rosenberg S (eds) J. B. Lippincott p 915, 1985.
17. Soloway MS: Cis-diamminedichloroplatinum II in advanced urothelial cancer. J Urol 120: 716-719, 1978.
18. Yagoda A, Watson R, Kemeny N, Bazzell W, Grabstald H, Whitmore W: CDDP and cyclophosphamide in the treatment of advanced urothelial cancer. Cancer 41: 2121-2130, 1978.
19. Douple E, Richmond E, Logan M: Therapeutic potentiation in a mouse mammary tumor and an intracerebral rat brain tumor by combined treatment with cis-dichlorodiammine platinum (II) and radiation. J. Clin Hematol Oncol 17: 585-603, 1977.
20. Wodinsky I, Swiniarski J, Kensler C, Venditti J: Combination radiotherapy and chemotherapy for lymphocytic leukemia in vivo. Cancer Chemoth Rep 4: 73-97, 1974.
21. Rowinsky EK, Donehower RC Drug Therapy: paclitaxel (Taxol). N Eng J Mad 332: 1004, 1996.
22. Tishler R, Schiff P, Geard C, Hall E. Taxol: a novel radiation sensitizer. Int J Rad Onc Biol Phys 22: 613, 1992.
23. Tishler R, Geard C, Hall E, Shiff P: Taxol sensitizes human astrocytoma cells to radiation. Cancer Ros 52: 3495, 1992.
24. Choy H, Rodrieguez F, Wilcox K, Koester S, Degen D: Radiation sensitizing effects of Taxotere (RP 56476) (Abstract) Proc Am Ascoc Cancer Res 33: 500, 1992.
25. Shipley W, Prout G, Einstein A et al: Treatment of invasive bladder cancer by cisplatin and radiation in patient's unsuited for surgery. JAMA 258: 931-935, 1987a.
26. Littbrand B, Edsmyr F, Reverz L: A low dose fractionation scheme for the radiotherapy of the carcinoma of the bladder. Experimental and preliminary results. Bull Cancer 62: 24, 1975.
27. Edsmyr F, Andersson L, Esposti P, Littbrand B, Nilsson B: Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radioth. Onc 4: 197-203, 1985.
28. Beahrs OH, Myers MH (eds): American Joint Committee on Cancer: Manual for staging of cancer, 2nd ed. Philadelphia, JB Lippincott, 1983.
29. World Health Organization - Handbook for reporting results of cancer treatment. Geneva. WHO Offset Publ, 48, 1979.
30. Rubin P, Constine LS: Von Ess J. Late effects of toxicity scoring Nat. Cancer Inst Monogr 6: 9-18, 1988.
31. Demit L: Combined treatment of radiation and cis-diammine c(II): a review of experimental and clinical data. Int J Rad Onc Biol Phys 13: 403-426, 1987
32. Carde P, Laval F: Effect of cis-diammine platinum and x-rays on mammalian cell survival. Int J Rad Onc Biol Phys 7: 929-933, 1981.
33. Tanabe M, Gobat D, Kallman R.: Effects of fractionated schedule of irradiation combined with cis-diamminedichloroplatinum II on the SCC VIVSF tumor and normal tissue Int J Rad Onc Biol Phys 13: 1523-1532, 1987.
34. Raghavan D, Pearson B, Dural P et al: Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer. J Urol 133: 399-402, 1985.
35. Sternberg C, Yagoda A, Schet H et al: Preliminary results of M-VAC for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
36. Blandy J, England H, Evans S, Hope-Stone H et al: T3 bladder cancer - the case for salvage cystectomy. Brit J Urol 52: 506, 1980.
37. Housset M, Maulard C, Chretien Y et al: Combined radiation and chemotherapy for invasive transitional - cell carcinoma of the bladder: a prospective study. J Clin Oncol 11: 2150, 1993.
38. Steineck G, Sher HI: Integrated therapy for advanced bladder cancer. Curr Opin Urol 4: 281, 1984.
39. Dunst J, Sauer R, Schrott K et al: Organ sparing treatment of advanced bladder cancer: a 10 - year experience Int J Rad Onc Biol Phys 30: 261, 1994.
40. Tester W, Caplan R, Heaney J et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14: 1996.
41. Kachnic La, Kaufman Ds, Zietman Al et al: Selective bladder preservation by combined modality therapy for invasive bladder cancer. Int J Rad Onc Biol Phys 1: 271, 1995.
42. Srougi M, Simon SD: Primary Methotrexate, Vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: 5 - year follow-up. J Urol 15: 593, 1994.
43. Sternferg CN, Raghaven D, Ohi Y, et al: Neoadjuvant and adjuvant chemotherapy in locally advanced disease: what are the effects on survival and prognosis. Int J Urol 2: 75, 1995.
44. Sternberg Cn, Pansodoro V, Lauretti et al: Neoajuvant MVAC chemotherapy and bladder preservation for muscle - infiltrating transitional cell carcinoma of the bladder. Urol Oncol 1995: 127.
45. Herr HW, Sher HI: Neoadjuvant chemotherapy and patrial cystectomy for invasive bladder cancer. J Clin Uncol 12: 975, 1994.
46. Given R, Parsons J, Mac Carley D et al: Bladder sparing multimodality treatment of muscle invasive bladder cancer: 5 - year follow - up. Urol 46: 499, 1995.
47. Tasker W, Porter A, Asbell C et al: Combined modality program with possible organ preservetion for invasive bladder carcinoma: results of RTOG Protocol 85 - 12. Int J Rad Onc Biol Phys 25: 783, 1993.
48. Jakse G, Rauschmeier H, Fritsch E, Frommhold H, Marberger H: Di integrierte Radiotherapie und Chemotherapie des lokal fortgeschrittenen Harnblasenkarzinoms. Aktuel Urol 17: 68-73, 1986.
49. Coppin C, Brown E: Concurrent cisplatin with radiation for locally advanced bladder cancer: a pilot study suggesting improved survival. Proc Am Soc Clin Oncol 5: 99, 1986.
50. Sauer R, Schrott K, Dunst J, Thiel H, Hermanek P, Born hof C: Preliminary results of treatment of invasive bladder carcinoma with radiotherapy and cisplatin. Int J Rad Onc Biol Phys 15: 871-875, 1986.
51. Schuhmann J, Gohde W: Experimentelle studien zur inaktivierung von tumorzellen durch kombination von chemo-und strahlentherapie. In: Kombinierte Strahlen - und Chemotherapie. Munchen - Wien -Baltimore: Urban und Schwarzenberg, 27-33, 1979.
52. Kyriazis H, Kereiaker J, Kyriazis A, Yagoda A: Chemotherapy of human bladder cancer in athymic mice: Effect of cisplatin of ionizing radiation. In: Proceedings of the 2nd National Bladder Cancer Conference, Sarasota, Florida, January 5-8, 106, 1983.
53. Weldon T, Kursh E, Novak L, Persky L: Combination radiotherapy and chemotherapy in murine bladder cancer. Urology 14: 47-52, 1979.
54. Mc Caffrey J, Hilton S, Bajorin D, Mazumdar M, Amsterdam A, Kim B, Sher H: Docetaxel in patients with advanced transitional cell cancer who failed cisplatin - based chemotherapy: a phase II trial. Proc Am Soc Clin Oncol 14: 233, AB: 607, 1995.
55. st line docetaxel in patients with metastatic urothelial cancer. Ann Oncol 5 (Suppl: 8), 67, AB: P331, 1994.
56. Sadam S, Bajorin D, Amsterdam A, Sher H: Docetaxel in patients with advanced transitional cell cancer who failed cisplatin - based chemotherapy: a phase II trial. Proc Am Soc Clin Oncol 13: 244, AB: 761, 1994.
57. Kaufman D, Prout G, Shipley W et al: Upfront MCV chemotherapy plus cisplatin and radiotherapy: its efficacy in successful bladder preservation in 50 patients with invasive cancer. Proc Am Soc Clin Oncol 8: 129, 1989.
58. Tester W, Porter A, Asbell S et al: Combined modality program with possible organ preservation for invasive bladder carcinoma. Proc Am Soc Clin Oncol 8: 141, 1989.